Thursday, May 14, 2026 9:54:39 PM
Thanks Meirluc,
I can believe that an AI found this information for you, but don't know why other AI's can't find the same information.
What's most important IMHO is that the EDEN's being tested and hopefully is so close that by the time the new cleanroom is ready it will be ready to produce within it. If not, that cleanroom will sit until the EDEN is ready.
I believe this is all saying an Orbis filing can come very shortly after approval. If the EDEN is Internationally accepted it shouldn't be difficult to establish CDMO's in the US, or perhaps the facility at Pittsburg is big enough to handle this effort. I don't believe ownership of the Pittsburg facility has been established, I gather Dr. Kalinski will teach at Pittsburg, but I'm uncertain if all the research work he's doing there is in the University, or will NWBO have a facility as well. I believe the least that he'll be is an official advisor to the company, but it's hard to say just how many people LP intends to make either full time, or part time employees or NWBO once we have an approval. I suppose someone who's considered to be full time staff could still teach classes.
Gary
I can believe that an AI found this information for you, but don't know why other AI's can't find the same information.
What's most important IMHO is that the EDEN's being tested and hopefully is so close that by the time the new cleanroom is ready it will be ready to produce within it. If not, that cleanroom will sit until the EDEN is ready.
I believe this is all saying an Orbis filing can come very shortly after approval. If the EDEN is Internationally accepted it shouldn't be difficult to establish CDMO's in the US, or perhaps the facility at Pittsburg is big enough to handle this effort. I don't believe ownership of the Pittsburg facility has been established, I gather Dr. Kalinski will teach at Pittsburg, but I'm uncertain if all the research work he's doing there is in the University, or will NWBO have a facility as well. I believe the least that he'll be is an official advisor to the company, but it's hard to say just how many people LP intends to make either full time, or part time employees or NWBO once we have an approval. I suppose someone who's considered to be full time staff could still teach classes.
Gary
Bullish
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
